​Effective December 31, 2024, emtricitabine/tenofovir disoproxil fumarate (F/TDF), generic equivalent of brand name Truvada, has been added to the PrEP-AP formulary for uninsured PrEP-AP client types. Generic sofosbuvir-velpatasvir (Epclusa) and glecaprevir/pibrentasvir (Mavyret) were added to the PrEP-AP formulary effective December 18, 2024, for all PrEP-AP client types.

On January 31, 2025, Gilead Advancing Access copay program will end their Patient Assistance Program (PAP) for brand name Truvada. An exception has been provided for individuals assigned female at birth, who can continue to access the Truvada PAP until July 31, 2025. As Truvada is the preferred PrEP medication for some people based on clinical indications and tolerability, PrEP-AP will add a generic version of Truvada to the PrEP-AP formulary for uninsured clients to ensure continued access. Please refer to ADAP MM 2024-26 Changes to Truvada PAP for further details on changes to the Gilead Advancing Access PAP.

The direct-acting hepatitis C virus (HCV) antivirals sofosbuvir/velpatasvir (Epclusa) and glecaprevir/pibrentasvir (Mavyret) have also been added to the PrEP-AP formulary. Chronic HCV infection causes liver inflammation that can eventually lead to cirrhosis, liver failure, and liver cancer, if untreated. HCV infection is curable with an 8 to 12-week course of direct-acting HCV antivirals, but many people on PrEP with HCV infection have not been able to access HCV treatment. By adding these HCV treatment options, CDPH hopes that providers can engage with and offer HCV treatment to PrEP-AP patients with untreated HCV infection.

For a full list of PrEP-related services covered by PrEP-AP, along with instructions for providers to bill PrEP-AP for administration, please see the PrEP-AP Resources webpage here: PrEP-AP Clinically Administered Medications. Uninsured clients, clients with confidentiality concerns, and minor clients must receive physician-administered medications from our contracted clinical providers who may be located here: PrEP-AP Clinical Providers and Enrollment Sites.

PrEP-AP requests that you share this information with your clinical leadership team and local prescribers. The PrEP-AP formulary (PDF)  has been updated to reflect the addition of the various gender-affirming medications.

If you have any questions regarding this new PrEP-AP benefit, please email PrEP-AP at PrEP.Support@cdph.ca.gov.

Thank you,

​
Joseph Lagrama

ADAP Branch Chief

California Department of Public Health